🇺🇸 Foghorn Therapeutics Inc.FHTX

Investor Event Form 8-K 01-10-2026 07:01:21 EDT

Subject: 8-K Items 2.05, 7.01, 9.01

Overview: Discontinuing FHD-909 and SMARCA2 programs with Lilly, reducing workforce by approximately 40%, and prioritizing proprietary programs to extend cash runway into 2029.

Source: SEC EDGAR · Original filing

Open document in a new tab

Get filings like this in Telegram the moment they are published — for the companies you follow.

Start 30-day trial About Finterest